[CORPORATE NEWS] Everfront Biotech Wins “Innovation Excellence Award” at the 2026 Taipei Biotech Awards; Cerebraca® Wafer Overcomes Post-Surgical Treatment Bottlenecks in Glioblastoma
Date: October 1, 2026
Everfront Biotech wins the “Innovation Excellence Award in the Pharmaceutical Category” at the Taipei Biotech Awards. Dr. Yu-Fang Hu (right), Chief Operating Officer of Everfront Biotech, represents the company in receiving the prestigious award from Taipei City Mayor Wayne Chiang (left).
Everfront Biotech announced that it has won the “Innovation Excellence Award in the Pharmaceutical Category” at the 2026 Taipei Biotech Awards—often regarded as the Oscars of Taiwan’s biotech industry—for its core product, “Cerebraca® Wafer: An Intracerebral Sustained-Release Implant Overcoming Post-Surgical Treatment Bottlenecks.” This prestigious accolade highly recognizes Everfront Biotech’s outstanding R&D capabilities and clinical translational value in the field of glioblastoma (GBM).
Precise Localized Drug Delivery Bridging the Critical Treatment Gap
Glioblastoma is characterized by high recurrence and drug resistance rates, presenting a highly challenging unmet medical need in clinical practice. Through an innovative localized sustained-release formulation, Cerebraca® Wafer directly bypasses the blood-brain barrier, effectively bridging the critical gap between tumor resection surgery and the initiation of standard adjuvant therapies. By utilizing a multi-targeted microenvironment intervention mechanism, this therapy not only demonstrates an excellent safety profile but also offers substantial clinical potential to significantly prolong the overall survival of patients with recurrent GBM.
Advancing Regulatory and Clinical Milestones to Accelerate Global Expansion
2026 marks a pivotal year of accelerated progress for Everfront Biotech. Following recent recognition from a leading international innovation award and the official agreement from the U.S. FDA in August to initiate the Phase IIb/III international clinical trial for Cerebraca® Wafer, this endorsement from industry, government, and academic authorities at the Taipei Biotech Awards further bolsters the company’s commercialization efforts. Driven by rigorous scientific data, Everfront Biotech will continue to collaborate with top-tier international CDMO partners, dedicated to bringing this breakthrough innovative therapy to the global stage.
Product Highlights of Cerebraca® Wafer:
Cerebraca® Wafer is a revolutionary implantable drug designed for the localized treatment of malignant brain tumors. Developed using multiple patented innovations, the product aims to solve critical challenges in brain cancer therapy—such as chemoresistance, high cancer stem cell content, and tumor recurrence.
Cerebraca® Wafer works by targeting receptor tyrosine kinase (RTK) signaling networks, modulating tumor resistance, and counteracting PD-L1-mediated immune evasion, a common barrier to effective treatment. In Phase I/IIa trials, no drug-related adverse effects were reported. Recurrent GBM patients showed a median overall survival of 15.7 months, with RTK-high subgroups reaching up to 26.2 months—a significant improvement over the current standard of care (6–9 months).
Everfront Biotech is actively seeking strategic partnerships and licensing opportunities to co-develop this promising therapy and extend its benefits to more patients worldwide.
Introduction to Everfront Biotech Inc.:
Everfront Biotech Inc. was founded in 2010, with a focus on research and development of new drugs, specifically the screening and further development of potential small molecules for clinical study. The company’s team is responsible for all aspects of product development, from front-end potential product development to pre-clinical research, chemistry manufacturing and controls (CMC), clinical trial submissions, and clinical trial planning and execution. To date, the Everfront Biotech team has successfully applied three clinical trials: Cerebraca® Wafer (for malignant brain tumors), HK-001 (for amyotrophic lateral sclerosis), and EF-009 (for pancreatic cancer), which have been approved for IND applications in both the United States and Taiwan.
Everfront Biotech’s new drug development is in line with national policies, and the Cerebraca® Wafer and HK-001 products were granted the certifications of biotech and new drug in 2016. The company has received the government subsidies in three science and technology projects as of 2022 from the Ministry of Economic Affairs.
Forward-Looking Statements
This press release contains forward-looking statements regarding the potential impact of clinical data, clinical development progress, regulatory milestones, and commercialization. Actual results may differ materially due to various risk factors, including but not limited to the safety profile of the drug candidate, clinical efficacy data, decisions by regulatory authorities, the availability of operational funding, and reliance on third-party contract manufacturing. Everfront Biotech assumes no obligation to publicly update or revise any forward-looking statements.
